Add-on combination therapy with monoclonal antibodies: Implications for drug development. — Three anti-amyloid monoclonal antibodies (MABs) including aducanumab, lecanemab, and donanemab have been approved by the FDA and lecanemab and donanemab are available in the US market and a variety of other national markets....

Evidence span

Add-on combination therapy with monoclonal antibodies: Implications for drug development. — Three anti-amyloid monoclonal antibodies (MABs) including aducanumab, lecanemab, and donanemab have been approved by the FDA and lecanemab and donanemab are available in the US market and a variety of other national markets....

From Cummings J et al. 2025, The journal of prevention of Alzheimer's disease

Method & conditions

Evidence type

experimental

Method

manual state transition; placebo-controlled clinical trial where source reports control arm

Species

Homo sapiens

Conditions

Humans; Alzheimer Disease; Antibodies, Monoclonal; Drug Therapy, Combination; Amyloid beta-Peptides — The journal of prevention of Alzheimer's disease 2025

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required